Drug Profile
SC 102 - Scotia
Latest Information Update: 04 Jul 2000
Price :
$50
*
At a glance
- Originator QuantaNova
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Photosensitisers; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Jul 2000 Discontinued-Preclinical for Cancer in United Kingdom (Unknown route)
- 14 Jul 1998 Profile reviewed
- 02 Aug 1995 Preclinical development for Cancer in United Kingdom (Unknown route)